论文部分内容阅读
临床和实验研究都已证明,肾素-血管紧张素-醛固酮系统(RAAS)在房颤的发生和发展中起关键作用。血管紧张素Ⅱ(AngⅡ)介导心房颤动的形态学底物心房间质纤维化的形成,抑制AngⅡ可以逆转心房颤动时心房重构的发生。血管紧张素转换酶抑制剂(ACEI)和血管紧张素Ⅱ受体阻断剂(ARB)通过对RAAS的干预,阻断AngⅡ介导心房纤维化的特异性信号转导通路,从而阻断心房重构的进程,预防或减少心房颤动的发生,有望成为未来心房颤动的非离子通道药物治疗处理策略。
Both clinical and experimental studies have demonstrated that the renin-angiotensin-aldosterone system (RAAS) plays a key role in the development and progression of atrial fibrillation. Angiotensin Ⅱ (AngⅡ) mediates the formation of atrial fibrillation, a morphological substrate for atrial fibrillation, and inhibition of Ang Ⅱ can reverse atrial fibrillation during atrial fibrillation. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) block the specific signal transduction pathways mediated by Ang II mediated atrial fibrosis by interfering with RAAS, thereby blocking atrial weight Structure of the process to prevent or reduce the occurrence of atrial fibrillation, is expected to become future non-ion channel atrial fibrillation drug treatment strategies.